January 4, 2024 02:50 PM EST
Cell/Gene Tx

Blue­bird snags more out­comes-based cov­er­age for its $3M+ sick­le cell gene ther­a­py

Zachary Brennan

Senior Editor

A sec­ond out­comes-based agree­ment with an uniden­ti­fied pay­er is now in the books for blue­bird bio’s new $3.1 mil­lion sick­le cell gene ther­a­py, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times